Skip to content
    Reviews

    Antibiotic Exposure Linked to Worse Survival in HNSCC and NPC: Review

    Psyllia et alCurrent Oncology Reports

    Antibiotic Exposure Linked to Worse Survival in HNSCC and NPC: Review
    Systemic antibiotics may alter gut and oral microbiomes, which could potentially influence the efficacy of cancer therapies. To assess the prognostic impact of antibiotic exposure in head and neck squamous cell carcinoma (HNSCC) and nasopharyngeal carcinoma (NPC), a systematic review and meta-analysis evaluated databases including PubMed/MEDLINE, Embase, and Scopus from January 2015 to March 28, 2026. Eligible investigations included patients receiving immune checkpoint inhibitors (ICIs), definitive chemoradiotherapy (CRT), or chemo-immunotherapy reporting overall survival (OS), progression-free survival (PFS), or objective response rate (ORR). Across 11 included studies representing 6,293 patients—9 of which (4,507 patients) contributed to survival meta-analyses using random-effects models—antibiotic exposure was associated with worse OS (HR 1.78, 95% CI 1.52–2.08) and PFS (HR 1.58, 95% CI 1.28–1.96). These associations remained consistent when stratified by treatment modality, showing poorer OS (HR 1.80, 95% CI 1.53–2.13) and PFS (HR 1.67, 95% CI 1.24–2.25) in ICI-treated cohorts, as well as inferior OS (HR 1.73, 95% CI 1.29–2.32) and PFS (HR 1.53, 95% CI 1.11–2.11) in definitive CRT cohorts. Heterogeneity was low to moderate for OS (I2 = 28.6%) and negligible for PFS (I2 = 0%), with leave-one-out sensitivity analyses yielding stable estimates for OS (HR range 1.76–1.86) and PFS (HR range 1.58–1.63). Inferior OS was observed whether antibiotic exposure occurred 30 to 60 days prior to ICI initiation (HR 2.04, 95% CI 1.43–2.90) or during concurrent/peri-treatment periods (HR 1.74, 95% CI 1.49–2.04). Additionally, ORR was descriptively lower in exposed individuals. Most analyzed studies carried a serious or high risk of bias, primarily attributed to confounding by indication. Given the observational nature of the current literature, causal inference cannot be reported, highlighting the need for prospective, microbiome-informed studies.

    Key Takeaways

    • Systemic antibiotic exposure around treatment initiation was associated with worse overall survival (HR 1.78, 95% CI 1.52–2.08) and progression-free survival (HR 1.58, 95% CI 1.28–1.96) across patients with head and neck squamous cell carcinoma and nasopharyngeal carcinoma.
    • Negative survival associations remained consistent in both immune checkpoint inhibitor cohorts (OS HR 1.80, 95% CI 1.53–2.13; PFS HR 1.67, 95% CI 1.24–2.25) and definitive chemoradiotherapy cohorts (OS HR 1.73, 95% CI 1.29–2.32; PFS HR 1.53, 95% CI 1.11–2.11).
    • Worse overall survival was linked to both 30- to 60-day pre-immunotherapy antibiotic exposure (HR 2.04, 95% CI 1.43–2.90) and concurrent or peri-treatment exposure (HR 1.74, 95% CI 1.49–2.04), while objective response rates were descriptively lower.
    Read the original sourceCurrent Oncology Reports